Respiratory medicine company Propeller Health stated on Thursday that it has passed the International Organization for Standardization (ISO) 13485:2016 certification for medical device quality management systems,
The ISO certification confirms the company is providing the best quality management systems and regulatory compliance for sensors, apps as well as services.
According to the company, the US FDA-cleared medical devices include sensors that attach to inhalers and mobile apps powered by a robust analytics platform helping patients better manage their asthma and COPD symptoms. The clinician tools are used by providers to help improve care and treatment and strengthen relationship with patients.
ISO is an independent, non-governmental international organisation with a membership of 162 national standards bodies based in Geneva, Switzerland. The 13485:2016 is the latest update to the ISO criteria, which was previously revised in 2003.
To achieve certification, the company spent six months undergoing independent review of the processes, documentation and general culture of quality in accordance with ISO guidelines. The ISO certification builds on the US FDA's quality management system principles and is recognised internationally.
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Arbele's ARB1002 receives US FDA Orphan Drug Designation
Compass Pathways wins FDA IND acceptance for COMP360 PTSD trial
Merck completes acquisition of Cidara Therapeutics for USD9.2bn
GSK wins European Commission approval for Shingrix prefilled syringe
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Oculis secures FDA Breakthrough Therapy Designation for Privosegtor in optic neuritis
Esco Aster partners with Shine-On Biomedical for HLA-G targeting exosome drug delivery platform
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA